MARKET

PEN

PEN

Penumbra
NYSE

Real-time Quotes | Nasdaq Last Sale

272.02
+5.11
+1.91%
Opening 11:01 03/08 EST
OPEN
267.56
PREV CLOSE
266.91
HIGH
272.29
LOW
261.53
VOLUME
53.82K
TURNOVER
--
52 WEEK HIGH
314.22
52 WEEK LOW
121.80
MARKET CAP
9.91B
P/E (TTM)
-615.7085
1D
5D
1M
3M
1Y
5Y
Neurosurgery Devices Market Analysis Report 2020-2025 | Global Industry Trends, Share, Size, Growth, Leading Key Players and Business Opportunity
SUPER MARKET RESEARCH · 5h ago
Global Intracranial Stents Market Derives Growth from Increasing FDA Approvals, says Fortune Business Insights
Mar 08, 2021 (The Expresswire) -- The global intracranial stents market is likely to grow in the coming years due to product advancements introduced in the...
The Express Wire · 6h ago
The Zacks Analyst Blog Highlights: Deere & Co, The Mosaic Co, Penumbra, Denbury and Goldman Sachs
The Zacks Analyst Blog Highlights: Deere & Co, The Mosaic Co, Penumbra, Denbury and Goldman Sachs
Zacks · 3d ago
Global Embolization Coils Market Analysis, Trend Forecast 2021-2027: Industry Overview, Development History, Leading Players, Revenue Expectation, Emerging Opportunities with Current Trends Analysis 2027
Mar 05, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." A recent research report on the Global...
The Express Wire · 3d ago
PENUMBRA DEADLINE ALERT
Mar 04, 2021 (NewMediaWire via COMTEX) -- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In...
NewMediaWire · 3d ago
Penumbra Deadline Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Penumbra To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 4, 2021) - Faruqi & Faruqi, LLP, a leadin...
Newsfile · 3d ago
PEN DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP - Important March 16, 2021 Deadline Reminder for Penumbra, Inc. Investors
RADNOR, PA / ACCESSWIRE / March 4, 2021 / The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against Penumbra, Inc. ("Penumbra") on behalf of those who purchased or acquired Penumbra (NY...
ACCESSWIRE · 3d ago
6 Surging Top Large Caps With Room to Grow on Reopening Hopes
Zacks.com · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PEN. Analyze the recent business situations of Penumbra through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PEN stock price target is 310.00 with a high estimate of 325.00 and a low estimate of 295.00.
EPS
Institutional Holdings
Institutions: 413
Institutional Holdings: 36.12M
% Owned: 99.10%
Shares Outstanding: 36.45M
TypeInstitutionsShares
Increased
104
4.67M
New
84
-1.06M
Decreased
84
1.95M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.33%
Healthcare Equipment & Supplies
+0.91%
Key Executives
Chairman/Chief Executive Officer/Director
Adam Elsesser
Chief Financial Officer
Maggie Yuen
Corporate Executive
James Pray
Executive Vice President/General Counsel/Secretary
Johanna Roberts
Executive Vice President
Lynn Rothman
Chief Accounting Officer
Lambert Shiu
Other/Director
Arani Bose
Independent Director
Harpreet Grewal
Independent Director
Don Kassing
Independent Director
Janet Leeds
Independent Director
Bridget O'Rourke
Independent Director
Surbhi Sarna
Independent Director
Thomas Wilder
No Data
About PEN
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.

Webull offers kinds of Penumbra Inc stock information, including NYSE:PEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PEN stock methods without spending real money on the virtual paper trading platform.